Clinical Trials Logo

Japanese Encephalitis Vaccine clinical trials

View clinical trials related to Japanese Encephalitis Vaccine.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01656200 Completed - Clinical trials for Japanese Encephalitis

A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Start date: May 2012
Phase: Phase 4
Study type: Interventional

Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006. JE vaccines give protection by generating a neutralizing antibody response, but both naturally exposed persons and patients with JE also have T cell responses. Whether JE vaccine SA14-14-2 elicits T cell responses is unknown. This study tests the hypothesis that T cell responses are generated in response to JE SA14-14-2 vaccination. The aim of this study is to characterize T cell responses to JE vaccine SA14-14-2 in healthy people, and to investigate differences in T cell responses between natural exposure, vaccination and disease.